ArticleOncotarget2017
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
Amir Noeparast et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
54 papers cite it
this paperpooled itcites it